Clinical Trial Update: Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada [NA]

View source ↗

Summary

Nanochon, Inc. announces a first-in-human early feasibility study of the Nanochon Chondrograft for knee cartilage lesions, currently recruiting in Canada.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cartilage Defects of the Knee

Drugs mentioned

• Nanochon Chondrograft

Snippet

Sponsor: Nanochon, Inc. | Conditions: Knee Cartilage Lesions | NA | Status: RECRUITING